If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

Share Price is delayed by 15 minutes
Get Live Data
534.00    8.00 (1.52%)
Bid:
533.00
Ask:
534.00
Spread: 1.00 (0.188%)
Market Cap: £307.66m
MAB1 Live PriceLast checked at - London Stock Exchange

Intraday Mortgage Advice Bureau Share Chart

Trading Update

23 Jan 2025 07:00

RNS Number : 3653U
Mortgage Advice Bureau (Hldgs) PLC
23 January 2025
 

 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for this announcement is Emilie McCarthy, CFO.

 

23 January 2025

 

Mortgage Advice Bureau (Holdings) plc

("MAB" or the "Group")

 

Trading Update

Board Changes

 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the year ended 31 December 2024, ahead of publishing its final results on Tuesday, 18 March 2025.

 

Year ended 31 December 2024

Group revenue for year ended 31 December 2024 increased by 11% to c.£266m (2023: £239.5m), which is significantly higher than the estimated 4% growth (1) in UK gross lending for the same period. The Board expects to report growth in Adjusted PBT for the year of c. 31% to c. £30.5m (2023: £23.2m) which is c. 4% ahead of consensus (2), excluding the £1.5m positive impact of the capitalisation of Midas platform internal development costs in 2024.

MAB's number of mainstream advisers grew modestly in the second half, increasing to 1,941 at the year-end (2023: 1918). However, lower than expected growth in adviser numbers was more than offset by a significant rise in productivity. The average revenue per mainstream adviser grew c.12% to c. £138k (2023: £123.5k). Improving operational efficiency is a key area of focus across the Group, supported by technology enhancements and lead-generation initiatives.

Current trading and outlook

Clear signs of pent-up demand were evidenced by the increase in mortgage applications in Q4 2024 (+15% compared to Q4 2023) and we expect this positive momentum to be maintained. UK Finance forecasts (1) gross new lending to rise 11% in 2025 in £235bn, which we believe is a realistic estimate.

In addition, the delivery of new technology enhancements and lead generation initiatives are expected to drive further growth this year, with many AR firms expecting to see adviser numbers increase, alongside a continued focus on increasing profitability through rising productivity.

 

 

 

 

 

Board changes

MAB is pleased to announce that subject to regulatory approval, Paul Gill, Chief Risk Officer, will be joining the Board as an Executive Director.

 

David Preece, Non-Executive Director, has decided not to seek re-election at the next AGM. The Board would like to thank David for his enormous contribution to MAB, as an Executive Director from 2004 to 2019, and as a Non-Executive Director since 2019.

 

The Board intends to add two additional Independent Non-Executive Directors.

 

Capital Markets Day

As previously announced, MAB will host a Capital Markets Day in London from 14:00 to 17:00 on 5 February 2025. The event will be held at the London Stock Exchange and will be webcast live for those who cannot attend in person.

 

The event will include updates on strategy, growth plans, technology and lead generation initiatives from our Executive Directors and members of our senior management team. We will also discuss medium-term targets and a proposed new capital allocation policy, further details of which will be pre-released via RNS on 4 February 2025.

 

If you would like to register your interest in the event, please contact Camarco: mab@camarco.co.uk.

 

 

Peter Brodnicki, CEO of MAB, commented:

"Despite two challenging years in terms of UK mortgage volumes, I am very pleased with how MAB has performed. We have increased strategic spend over this period and are starting to see the benefits of this come through in the positive momentum we're building.

 

We expect purchase transactions to steadily increase over the next year, whilst several years of strong refinancing transactions will provide additional opportunities for growth.

 

We are seeing increased optimism among many of our ARs, and as a result, expect to see organic growth in adviser numbers start to return in a more meaningful way. Following a slower period in terms of new AR recruitment, we plan to onboard more firms this year while continuing to explore value-accretive acquisitions.

 

The step up in productivity in 2024 has been very pleasing, so our focus for this year is on maintaining that momentum, supported by development in technology and AI, and our continued focus on lead generation."

 

(1) - UK Finance Mortgage Market Forecasts published in December 2024

(2) - Consensus estimate 2024 adjusted PBT - £29.2m. 

 

 

Enquiries:

 

Mortgage Advice Bureau (Holdings) plc

Via Camarco

 

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Emilie McCarthy, Chief Financial Officer

 

Nominated Adviser and Joint Broker

Keefe, Bruyette & Woods, a Stifel Company

Erik Anderson / Nick Harland / Francis North / Harry Billen

 

 

+44 (0)20 7710 7600

Joint Broker

Peel Hunt LLP

Andrew Buchanan / Oliver Jackson

 

 

 

+44 (0) 20 7418 8900

Financial PR

Camarco

Tom Huddart / Louise Dolan / Letaba Rimell

 

 

mab@camarco.co.uk

+44 (0) 203 757 4980

Investor Relations

Investor.relations@mab.org.uk

 

About Mortgage Advice Bureau:

 

MAB is one of the UK's leading consumer intermediary brands and specialist networks for mortgage advisers. 

 

Through its partner firms known as Appointed Representatives ("ARs"), MAB has approximately 2,000 advisers providing expert advice to customers on a range of mortgage, specialist lending, protection, and general insurance products. MAB supports its AR firms with proprietary technology and services, including adviser recruitment and lead generation, learning and development, compliance auditing and supervision, and digital marketing and website solutions.

 

For more information, visit www.mortgageadvicebureau.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFFILDIFFIE
Date   Source Headline
13th Jul 20235:03 pmRNSBlock listing Interim Review
11th Jul 20237:00 amRNSDirectors' Shareholdings and PDMR notification
30th Jun 202312:08 pmRNSDirector/PDMR Shareholding
16th Jun 202311:49 amRNSDirector/PDMR Shareholding
13th Jun 20234:39 pmRNSTR-1: Notification of major holdings
1st Jun 202311:52 amRNSDirector/PDMR Shareholding
24th May 20235:16 pmRNSResult of AGM
24th May 20237:00 amRNSAGM Statement
16th May 20232:23 pmRNSPDMR Dealing and Total Voting Rights
28th Apr 20231:53 pmRNSDirectors' Shareholdings and PDMR notification
27th Apr 20234:39 pmRNSNotification of major holdings
20th Apr 20234:29 pmRNSPosting of Report and Accounts and Notice of AGM
17th Apr 20235:08 pmRNSPDMR dealing and Total Voting Rights
31st Mar 20232:25 pmRNSDirectors' Shareholdings and PDMR notification
28th Mar 20237:00 amRNSFinal Results for the year ended 31 December 2022
14th Mar 20235:05 pmRNSDirectors' Shareholdings and PDMR notification
9th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20233:35 pmRNSNon-Executive Director Board change
2nd Mar 20234:35 pmRNSPrice Monitoring Extension
28th Feb 20231:54 pmRNSDirectors' Shareholdings and PDMR notification
24th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20235:06 pmRNSDirectors' Shareholdings and PDMR notification
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20234:29 pmRNSDirectors' Shareholdings and PDMR notification
31st Jan 20237:00 amRNSTrading Update
17th Jan 20234:07 pmRNSDirectors' Shareholdings and PDMR notification
3rd Jan 20239:54 amRNSDirector's Shareholdings and PDMR notification
21st Dec 20227:00 amRNSAppointment of Joint Broker
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
14th Dec 20221:51 pmRNSDirectors' Shareholdings and PDMR notification
1st Dec 20227:00 amRNSTrading Update
30th Nov 20224:50 pmRNSDirectors' Shareholdings and PDMR notification
14th Nov 20224:15 pmRNSPDMR dealing notification and Total Voting Rights
7th Nov 20225:01 pmRNSDirectors' Shareholdings and PDMR notification
31st Oct 20221:18 pmRNSDirectors' Shareholdings and PDMR notification
14th Oct 20225:04 pmRNSDirectors' Shareholdings and PDMR notification
6th Oct 20225:16 pmRNSHolding(s) in Company
6th Oct 20227:00 amRNSDirectors' Shareholdings and PDMR notification
4th Oct 20224:27 pmRNSHolding(s) in Company
3rd Oct 20225:13 pmRNSTotal Voting Rights
3rd Oct 20225:11 pmRNSHolding(s) in Company
30th Sep 202210:21 amRNSDirectors' Shareholdings and PDMR notification
27th Sep 20227:00 amRNSInterim Results
16th Sep 202210:36 amRNSDirectors' Shareholdings and PDMR notification
31st Aug 202212:53 pmRNSDirectors' Shareholdings and PDMR notification
16th Aug 202210:27 amRNSDirector/PDMR Shareholding
8th Aug 20224:36 pmRNSDirectors' Shareholdings and PDMR notification
29th Jul 20221:03 pmRNSPDMR dealing notification and Total Voting Rights
28th Jul 20224:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.